Lumexa Imaging (LMRI) Q3 2026 earnings review
Lumexa's scan volumes speed up, but overhead trims operating profit
Lumexa Imaging's outpatient scan centers resumed growing cash profit after standing still in the first half, though corporate overhead and legal bills weighed on reported earnings. Third-quarter revenue rose 5% and Adjusted EBITDA — operating cash profit excluding one-offs — climbed 6% as higher-priced MRI and CT scans reached a record share of volume. Chief executive Caitlin Zulla held the full-year revenue and cash profit midpoints while raising the adjusted earnings per share outlook on a lower tax rate.
| Consolidated revenue | $272.0M +5.0% from a year ago (system-wide +7.7%) |
|---|---|
| Operating cash profit (Adjusted Ebitda) | $62.6M +5.9% from a year ago (23.0% margin) |
| Profit per share, excluding one-offs | $0.26 $0.13 a year ago |
| Full-year outlook | EPS raised $0.14 Revenue and $238M Adjusted Ebitda midpoints held |
⚖️ Verdict: 🟢 Bullish
The story got better because third-quarter operating cash profit accelerated enough to take pressure off the rest of the year. After flat first-half results, hitting the unchanged full-year plan now requires 6% fourth-quarter Adjusted EBITDA growth by our math, inline with the third quarter's pace. Two cautions: corporate overhead jumped on stock pay and $3.6 million of legal bills, and total centers shrank by two to 190 even as quarterly cash equipment spending doubled the company's target to $14 million.
The question now is whether majority-owned clinics are recovering their profit margins alongside the fast-growing hospital joint ventures. If maturing clinics cover wage costs and open on schedule, fourth-quarter cash profit will clear last year's tough comparison; if clinic closures and overhead persist, joint-venture gains alone will carry the business. The third-quarter 10-Q segment tables and fourth-quarter center openings will tell.
🐂 Bull Case
Operating Profit Resumed Growing as Scans Sped Up
Lumexa runs outpatient medical imaging centers, both on its own and in joint ventures with hospital systems. For the first two quarters of the year, Adjusted EBITDA — operating cash profit excluding one-offs and stock pay — barely grew, leaving the full-year plan dependent on a second-half rebound.
That rebound started in the third quarter. Adjusted EBITDA rose 5.9% from a year ago to $62.6 million, lifting the margin by 0.2 percentage points to 23.0% of revenue. Same-center advanced scan volume — MRI and CT scans at locations open at least a year — sped up to 6.8% growth across the full network, up from 4.9% in the second quarter.
Because the company absorbs approximately $7 million in new public-company overhead this year, underlying cash profit growth is about 3 percentage points faster than the headline rate. That keeps the full-year target within reach without needing a fourth-quarter spike.
What to watch: fourth-quarter Adjusted EBITDA against the $67.8 million implied by the middle of the full-year outlook. Meeting that figure against last year's tough fourth-quarter comparison would settle the back-half execution concern.
Higher-Priced MRI and CT Scans Reached a Record Share
Lumexa's growth plan rests on shifting its scan mix toward advanced modalities — complex MRI and CT scans that insurers reimburse at three to four times the rate of routine X-rays and ultrasounds. Chief executive Caitlin Zulla said that "Advanced modalities reached a record high as a percent of our volumes" during the third quarter.
- System-wide advanced scan share: 38.2% of total procedures, up 1.5 percentage points from a year ago
- Consolidated advanced scan share: 31.8% of procedures at majority-owned centers, up 1.3 percentage points
- Consolidated advanced scan volume: up 7.9% from a year ago, compared with 1.7% growth for routine scans by our math
That shift in mix helped lift net patient service revenue per consolidated procedure by 1.1% from a year ago to $334.50, by our math, even as total consolidated procedures rose 3.6%. What to watch: same-center revenue per scan in the third-quarter filing, which will show whether insurer payment rates matched the richer scan mix.
Lower Interest Bills Turned Losses Into Cash and Profit
After using proceeds from its late-2025 initial public offering to pay down debt and repricing its remaining term loan in June, Lumexa pays roughly half as much interest as it did a year ago. Zulla said the business's operating progress is "translating into strong, durable cash generation".
Third-quarter interest expense dropped to $15.7 million from $30.6 million a year earlier, and down $0.5 million from the second quarter. That savings turned a year-ago net loss of $3.5 million into $7.2 million of net income. By our math, third-quarter free cash flow — operating cash flow minus property and equipment purchases — reached $20.6 million, bringing the nine-month total to $41.4 million.
What to watch: fourth-quarter free cash flow against the $18.6 million to $28.6 million needed to hit the $60 million to $70 million full-year target. Hitting that range will prove cash generation holds up despite higher equipment spending.
Positives this quarter didn't test
Three standing growth drivers from earlier quarters received no new figures in the third-quarter earnings release and await the conference call or quarterly filing.
- PET scan volume and machines: volume grew over 23% in the first half with two new machines added in July; the call will show whether the eleventh machine opened on schedule.
- FastScan MRI software roll-out: targeted for two-thirds of the MRI fleet by year-end, up from 51% at the start of 2026.
- Hospital joint-venture pipeline and Medicare payment rules: updates on the Hospital for Special Surgery partnership and final 2027 outpatient payment rates arrive on the call and in year-end reporting.
🐻 Bear Case
Overhead and Legal Bills Cut Into Reported Profit
While Lumexa's clinic-level costs improved — cost of operations excluding depreciation fell by 1.7 percentage points of revenue to 82.9% — corporate overhead moved the other way. General and administrative expenses jumped 75.8% from a year ago to $30.0 million, rising from 6.6% of revenue to 11.0%.
- GAAP operating income: $28.1 million, down 7.3% from $30.3 million a year ago
- Stock-based compensation: $12.3 million in Q3, up from $8.3 million a year ago
- Litigation and settlement costs excluded from Adjusted EBITDA: $3.6 million in Q3, up from $1.2 million in Q2
- Strategic systems and finance consulting excluded from Adjusted EBITDA: $2.4 million in Q3, double last year's $1.2 million
The company excludes stock pay, system implementation bills, and legal expenses for "matters not related to core operations" from its adjusted figures. Because those excluded bills totaled $20.2 million before tax this quarter, adjusted profit grew while reported operating profit shrank. What to watch: whether litigation expenses in the quarterly filing are tied to the April vendor data breach class actions.
Total Center Count Shrank Despite Expansion Plans
Zulla said the imaging operator's newer clinics are ramping on plan and that the team is "actively opening three new de novo centers and are on pace to achieve our goal for 8–10 new center openings this year". Having opened only two new centers in the first half, the company must open six to eight in the second half.
Yet the release's volume table shows total centers fell from 192 at the end of June to 190 at the end of September, with both majority-owned centers (down one to 103) and joint-venture sites (down one to 87) shrinking. A footnote notes "certain exit costs related to closed outpatient imaging centers". At the same time, third-quarter cash property and equipment purchases jumped to $14.2 million by our math, more than double management's $5 million to $7 million quarterly framework.
What to watch: the center roll-forward table in the quarterly filing. If closures offset new openings while capital spending runs above plan, network growth will deliver less revenue per dollar spent.
Risks this quarter didn't answer
Four standing operational and balance-sheet risks cannot be checked from the earnings release alone because the detailed tables live in the quarterly Form 10-Q filing.
- Outpatient segment cash profit: fell 4.6% in the first half on wage and supply inflation; the release prints Q3 Outpatient revenue ($201.9 million, up 2.9% from Q2) but omits segment Adjusted EBITDA.
- Same-center price per scan and payer mix: consolidated revenue per scan lagged system-wide growth in Q2 (+0.6% vs +2.2%); the 10-Q MD&A table will show Q3's split.
- Baylor joint-venture concentration: the BTDI partnership supplied 78% of joint-venture earnings in Q2; Note 11 in the 10-Q will show Q3's share.
- Off-balance-sheet joint-venture debt: rose from $69.1 million at year-end to $81.2 million in Q2; the 10-Q footnotes will update the balance.
💲 Other KPIs
Lumexa's share of profit from its 87 unconsolidated hospital joint-venture centers rose 27.0% from a year ago, accelerating from 12.7% growth in the second quarter. Over the first nine months, cash distributions paid by those joint ventures to the parent company climbed 33.5% to $55.0 million, nearly matching the $56.5 million of book earnings.
Combined patient, related-party, and other receivables grew 15.0% from the end of 2025 by our math, outpacing consolidated revenue growth of 4.4% over the nine-month period. Other receivables jumped 74.5% to $33.2 million, creating a $14.2 million working-capital cash drain on the nine-month cash flow statement.
Total debt plus finance lease liabilities stood at $891.9 million, up $14.9 million since year-end as the imaging group added $10.0 million in net new equipment finance leases. Because cash on hand grew by $31.2 million to $90.0 million, net debt fell 2.0% from the end of 2025 by our math.
Weighted-average diluted shares rose 38.4% from a year ago due to the late-2025 initial public offering, which cuts per-share growth rates relative to total dollar profit growth. Sequentially, the diluted count edged up 0.2% from 96.0 million in the second quarter.
🔮 Guidance
Unchanged. The middle of the range stays at $1.071 billion, or 4.7% growth for the year. By our math, that leaves $282.3 million for the fourth quarter, or 5.5% growth from a year ago — slightly faster than the third quarter's 5.0% pace despite lapping last year's strong fourth quarter.
Unchanged at the middle of the range. Management narrowed the band by $1 million on each side around the $238 million midpoint, which represents 3.4% growth (or 6.5% by our math before $7 million of "public company costs that were not incurred in 2025"). By our math, that leaves $67.8 million for the fourth quarter, up 6.3% from a year ago at a 24.0% margin.
Raised. Lumexa lifted the middle of the range by $0.14 to $0.88 per share, "driven by lower assumed effective tax rate" after nine-month adjusted earnings reached $0.64 per share. By our math, the new outlook leaves $0.24 per share for the fourth quarter, down slightly from $0.26 in the third quarter.
❓ Key Questions
Why did total centers drop from 192 to 190?
Management says it is actively opening three new clinics and remains on pace for 8 to 10 openings this year, yet total centers fell by two in the third quarter. Investors need the exact count of gross openings and closures.
Why did Q3 cash equipment spending double the target?
By our math, third-quarter cash purchases of property and equipment hit $14.2 million, up from $9.7 million in the second quarter and more than double the $5 million to $7 million quarterly framework. Did the company buy equipment early for fourth-quarter openings?
What drove the $3.6 million legal charge in Q3?
Litigation and settlement add-backs jumped from $1.2 million in the second quarter to $3.6 million in the third. Management has not stated how much of this cost stems from the consolidated April vendor data breach lawsuits.
Did Outpatient segment cash profit stop falling in Q3?
Adjusted EBITDA in the core majority-owned Outpatient segment fell 8.2% in the first quarter and 1.3% in the second due to wage and supply inflation. The release gives segment revenue ($201.9 million) but leaves segment profit for the 10-Q filing.
What caused other receivables to jump by $14 million?
Other receivables on the balance sheet rose from $19.0 million at year-end to $33.2 million in September. Clarifying whether this relates to delayed insurer collections, joint-venture pass-through bills, or tax refunds will show if the cash drain will reverse.